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Abstract
Mild cognitive impairment (MCI) often presages development of Alzheimer’s disease (AD). We
recently completed a cross-sectional study to test the hypothesis that a combination of a brief
cognitive screening instrument (Mini-Cog) with a functional scale (Functional Activities
Questionnaire; FAQ) would accurately identify individuals with MCI and undiagnosed dementia.
The Mini-Cog consists of a clock drawing task and 3-item recall, and takes less than 5 minutes to
administer. The FAQ is a 30-item questionnaire completed by an informant. In addition to the Mini-
Cog and FAQ, a traditional cognitive test battery was administered, and two neurologists and a
neuropsychologist determined a consensus diagnosis of Normal, MCI, or Dementia. A classification
tree algorithm was used to pick optimal cutpoints, and, using these cutpoints, the combined Mini-
Cog and FAQ (MC-FAQ) predicted the consensus diagnosis with an accuracy of 83% and a weighted
kappa of 0.81. When the population was divided into Normal and Abnormal, the sensitivity,
specificity and positive predictive value were 89%, 90%, and 95%, respectively. The MC-FAQ
discriminates individuals with MCI from cognitively normal individuals and those with dementia,
and its ease of administration makes it an attractive screening instrument to aid detection of cognitive
impairment in the elderly.
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INTRODUCTION
Alzheimer’s disease (AD) affects 10% of the population aged 65 and over [30]. Prior to the
development of overt dementia, many individuals experience milder symptoms classified as
mild cognitive impairment (MCI), which is often a prodromal stage of AD. Longitudinal
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studies have estimated that approximately 3%–19% of the elderly suffer from MCI, and that
approximately 11%–33% convert from MCI to dementia over a 2-year period [15]. This large
range of estimates stems partly from the fact that there is no universally accepted definition of
MCI. However, MCI is generally understood to involve a cognitive complaint and evidence
of cognitive decline, but without significant impairment of daily activities. In contrast, AD is
characterized by substantial cognitive deficits in at least two domains (including memory) of
sufficient severity to impair normal activities [26,28].
It is thought that there is widespread under-ascertainment of AD, with estimates that fewer
than 50% of cases are diagnosed, and only approximately 25% are treated [30]. Under-
ascertainment of MCI is presumably greater still, but accurate data are lacking. Although there
is no current treatment to stop the progression of AD, drug treatments can improve dementia
symptoms, and ideally, these treatments should be employed at the earliest stages of disease
in order to sustain individuals at their highest level of functioning. While current drug
treatments have not proven effective in preventing conversion of MCI to dementia, individuals
with MCI benefit symptomatically from the use of cholinesterase inhibitors with some evidence
for beneficial effects on disease progression [25]. Moreover, numerous investigational agents
are under study as potential disease-modifying effects that may prevent or slow progression of
AD. Given the likely under-ascertainment of MCI, and the requirement for early detection for
application of new therapeutics, simple and effective tests are needed to screen for cognitive
impairment among the elderly.
METHODS
Study population
We used two primary sources for the individuals included in this study. Patients without prior
history of dementia were identified in the outpatient Geriatric Medicine Clinic at Wesley
Woods Center of Emory University School of Medicine (n = 102). Geriatricians referred
patients if they suspected possible cognitive deficits, or if patients or family expressed concern
about cognitive decline. Additional participants were collected prospectively from individuals
who were being enrolled as cognitively intact controls or possible MCI participants in a registry
of research volunteers at the Emory Alzheimer’s Disease Research Center (n = 76). Participants
were eligible for the study if they had a valid Mini-Cog score, a clinical diagnosis, and a
Functional Activities Questionnaire (FAQ). Altogether, 204 participants had a Mini-Cog and
a clinical diagnosis, but we only included the 178 eligible participants that also had the FAQ.
An additional 26 subjects had the Lawton-Brody IADL [19] instead of the FAQ, and these
individuals were excluded from the analyses. Six additional eligible individuals were excluded
due to missing FAQ data because we were unable to corroborate functional information from
a reliable informant. All study procedures were conducted with approval and in accordance
with the ethical standards of Emory University’s Institutional Review Board.
Mini-Cog administration and scoring
There are a variety of methods of conducting the Mini-Cog test. In our case, the tester recited
3 words (apple, penny, table) and then had the patient repeat them verbally. The patient was
instructed that he/she should try to remember the words because they would be asked to recall
them later. Next, the patient was presented with a pre-drawn circle on a piece of paper and told,
“I want you to imagine that this circle is the face of a clock. Place all the numbers on the clock
and set the time to ten minutes after eleven.” After the clock was completed, the patient was
asked to recall the 3 words they were given earlier. There was no specific time limit for the
clock drawing test (CDT), but the task typically took less than 5 minutes. The three-word recall
and CDT were each worth 3 points. Each correctly recalled word was given one point, and the
CDT was scored as follows:
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1 point: All numbers present with no omissions, duplications, or superfluous markings.
1 point: The numbers 12, 3, 6, 9 were on or adjacent to quadrant boundaries. All numbers
were upright in the pre-drawn circle near the edge.
1 point: Hands indicated 11:10 by placement and proportion. Scorer was able to tell the
intended time without knowing what time the participant was told to draw.
Functional activities questionnaire (FAQ)
The FAQ [27] was completed by a reliable informant, generally a spouse, other family member,
or close friend. The questionnaire is self-explanatory, and informants were asked to complete
the form while the research participant was performing other tasks. Time required to complete
the FAQ was not collected as this was completed without the involvement of staff. The
completed form was collected, scored, and recorded. Performance on each of ten items
reflecting instrumental activities of daily living (IADL) was reported as ‘normal’, ‘has
difficulty but does by self’, ‘requires assistance’, or ‘dependent’ (scored 0 to 3, respectively).
A score of 30 represents maximal dependence, and a score of 0 represents complete
independence. Pfeffer and colleagues originally suggested the following cutoffs: normal
functioning ~3, questionably affected ~12, mildly affected ~15, moderately affected ~23, and
severely affected ~29 [27].
Cognitive testing battery
All participants were tested with a common battery of neuropsychological tests, including the
Mini-Mental State Examination (MMSE) for global functioning and two tasks in each of five
cognitive domains.
Memory: CERAD Word List [23] and Brief Visuospatial Memory Test-Revised [3].
Language: Boston Naming Test [18] and Controlled Oral Word Association [4]
Attention: Digit Span Forward [35] and Trail-Making, part A [1]
Executive Function: Trail-Making, part B [1] and Clock Drawing Test [14]
Visuospatial ability: Digit-Symbol [34] and Judgment of Line Orientation [5]
Results of the cognitive tests were converted to z-scores using standard age-specific norms.
For the CER-AD word list test, norms were also adjusted for education. The CDT portion of
the cognitive battery was scored differently than the Mini-Cog by using an elaborated 13-point
scale with published norms [14]. The neuropsychologist was not blinded to Mini-Cog as 3 item
recall (in MMSE) and CDT were included in the testing, but the FAQ was not included in the
neuropsychological assessment.
Consensus diagnosis
Two experienced behavioral neurologists (AIL, JJL) individually reviewed clinical history of
all participants. The neurologists did not have access to the Mini-Cog or FAQ results, but they
did review the cognitive testing results and the neuropsychologist’s (FCG) impression. All
participants were diagnosed as Normal, MCI, or Dementia. The classification of MCI was not
limited to those with memory impairment (MCI-amnestic), and includes individuals who
demonstrated impairments in other single domains or multiple domains. For those
demonstrating difficulties in multiple cognitive domains, designation as either MCI or
Dementia was generally driven by review of records to obtain a sense of the individual’s
functional independence. The neurologists agreed on initial diagnosis for 90% of cases
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(184/204), and the weighted kappa was 0.90. In case of differing diagnoses, a consensus
diagnosis was reached through discussion among all clinicians.
Determination of optimal cutpoints
We used a classification tree algorithm (CART, or Classification and Regression Trees [9])
implemented in R [33] to determine the best cutpoints for the Mini-Cog and FAQ to predict
Normal, MCI, and Dementia diagnoses. The CART algorithm selects optimal cutpoints by
recursively partitioning the observations to achieve the maximum reduction in the Gini index,
a measure of disparity between the predicted and observed values. In our study we penalized
misclassification across two ordered categories (e.g., Dementia classified as Normal) twice as
much as misclassification across adjacent categories (e.g., Dementia classified as MCI). We
also considered possible modifying effects of age, sex, education, and race to determine
whether optimal cutpoints might differ by these variables.
Statistical analyses
Three-by-three tables, comparing gold standard diagnosis (consensus diagnosis) vs. prediction
based on cutpoints for Mini-Cog and FAQ scores as determined by the tree algorithm, were
evaluated via calculation of accuracy and weighted kappa statistics. In addition, we used a
polytomous logistic model, with no proportional odds assumption, in which the outcomes were
the true diagnostic categories of Normal, MCI, and Dementia. We used this model to: 1)
compare other cognitive tests with the Mini-Cog and FAQ using model fit to evaluate which
tests best predicted the consensus diagnosis; and 2) to evaluate which demographic variables
were significant predictors of outcome when cognitive tests were already in the model. Finally,
analyses were conducted using only two diagnostic categories, Normal vs. Abnormal (MCI
and Dementia combined). Cut-points from the original analyses were used to separate Normal
from Abnormal. Restriction of the data to two diagnostic categories made possible calculation
of standard statistics such as sensitivity, specificity, and positive predictive value.
RESULTS
Descriptive characteristics
Table 1 presents descriptive statistics for the 178 participants. The overall average age of
subjects was 77. The subjects were 22% African-American, 72% female, and 37% had a high
school education or less. The proportions diagnosed as Normal, MCI, and Dementia were 38%,
30%, and 32%, respectively. Groups differed significantly by age, education, and race. A higher
percentage of females were present in the Dementia group than Normal, but the MCI group
did not differ from the Normal group for sex. As expected, Dementia, MCI, and Normal groups
differed significantly on Mini-Cog, MMSE, and FAQ scores after adjusting for demographic
covariates.
Determination of Mini-Cog and FAQ cutpoints and comparison of true diagnosis versus
predicted
Table 2 shows the cutpoints used for the Mini-Cog and FAQ to classify participants into
diagnostic categories. These cutpoints were chosen via CART to optimize overall agreement
between test results and the final diagnosis. Additional analysis of the relationship between
separate components of the Mini-Cog and FAQ with age and education were examined by
univariate Spearman correlations. Correlations between education and 1) the clock score and
2) the 3 word recall were 0.44 and 0.32, respectively (both p < 0.0001). Univariate Spearman
correlations between age and 1) the clock score and 2) the 3 word recall were −0.42 and −0.29,
respectively. The univariate Spearman correlation between the FAQ and 1) age and 2) Mini-
Cog score were 0.37 and −0.36 respectively. In the CART algorithm, age was the only
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demographic covariate that provided any increase in accuracy after Mini-Cog and FAQ scores
were used, but the increase was small (85% vs. 83%) and it complicated the classification
criteria, increasing the number of discrete categories from seven to eleven. For increased
simplicity, we did not include age with the Mini-Cog and FAQ scores for determining optimal
cutpoints. Among those with significant functional limitations (FAQ > 12), only those who
scored a perfect 6 points on the Mini-Cog were classified as MCI. All others in this group were
classified as Dementia. Classification of subjects based on functional (FAQ) and cognitive
(Mini-Cog) axes are shown in Fig. 1.
Table 3a shows the agreement between classification based on the Mini-Cog and FAQ (MC-
FAQ) and the clinical diagnosis. The accuracy was 83%, and the weighted kappa was 0.81.
For comparison, Table 3b shows the agreement between classification based on the MMSE
and the FAQ (MMSE-FAQ). The accuracy was 85% and the weighted kappa was 0.83.
Importantly, among true MCI, 74% (39/53) were correctly classified as MCI by the MC-FAQ
screener compared to 68% (36/53) by the MMSE-FAQ screener.
Polytomous logistic regression analyses
The polytomous logistic regression model using diagnosis as the outcome and Mini-Cog, FAQ,
age, race, gender, and education as predictors indicated that only Mini-Cog, FAQ, and age
were significant predictors of clinical diagnosis. This was consistent with the classification
tree, and suggests that once these predictor variables were used, no additional predictive
information was gained by considering race, gender, or education.
Table 4 shows results of polytomous logistic regression analyses for a variety of models using
different cognitive tests as predictors. Higher values indicate a better fitting model. In the
cognitive battery, executive and memory domain tests were better predictors of diagnosis than
visuospatial, language, and attention domain tests. They were also superior to the Mini-Cog
when it was considered individually. In this model, both the Mini-Mental State Exam (MMSE)
and the FAQ alone performed better than the Mini-Cog alone. The best tests were the MMSE-
FAQ and the MC-FAQ, with the MMSE-FAQ yielding a better fitting model than MC-FAQ.
The superior performance of the MMSE may reflect the greater range of continuous variables
allowed by the MMSE compared to Mini-Cog for the polytomous logistic regression analysis
(0–30 vs. 0–6, respectively). However, after deriving optimum cut-points via the classification
tree algorithm, both pairs of tests gave similar results for accuracy and weighted kappas (0.83
and 0.81 for MC-FAQ, and 0.85 and 0.83 for MMSE-FAQ; Tables 3a and 3b). These findings
indicate that the MMSE may offer a small advantage over the Mini-Cog as a cognitive screen
when each is paired with the FAQ. However, this came at the expense of time, as the MMSE
took about 10–15 minutes to administer, while the Mini-Cog required 3–5 minutes.
Sensitivity, specificity, and positive predictive value
We next examined the ability of the MC-FAQ and MMSE-FAQ to distinguish between
‘normal’ and ‘not normal’. This perspective is appropriate when considering a general elderly
population, in which the true diagnosis is not known but we wish to detect possible cases of
either MCI or undiagnosed Dementia for further work-up. In this case, true Dementia cases
and true MCI cases were collapsed into a single ‘Abnormal’ category, and the same was done
with the test results. Using the cutpoints shown in Table 3 for Normal vs. Abnormal, the
sensitivity (proportion of true positives who test positive) and specificity (proportion of true
negatives who test negative) of the MC-FAQ screener were 89% (98/110) and 90% (61/68),
respectively, while the positive predictive value (proportion of test positives who are truly
positive) was 95% (98/103). For comparison, a similar analysis was performed for the MMSE-
FAQ, using optimal cutpoints determined by the classification tree algorithm. The sensitivity,
specificity, and positive predictive value of the MMSE-FAQ were 90% (99/110), 93% (63/68),
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and 96% (99/103), respectively. These results suggest that a combination of either MMSE or
Mini-Cog with the FAQ can effectively identify individuals with both Dementia and MCI,
with the MMSE-FAQ performing slightly better than the MC-FAQ overall. However,
administration of the MMSE required 2–5 times longer than the Mini-Cog, and the MC-FAQ
more accurately classified MCI cases (74%) than the MMSE-FAQ (68%).
DISCUSSION
The primary purpose of our study was to determine whether a combination of a brief cognitive
screening test (Mini-Cog) along with a measure of functional ability (FAQ) would effectively
discriminate between cognitively normal elderly, those with MCI, and those with dementia.
Since both cognitive performance and functional abilities are implicit in the concepts of MCI
and dementia, we reasoned that adding the FAQ to a cognitive screener would improve the
ability to detect these conditions. By using simple cutpoint rules for the MC-FAQ, we were
able to correctly classify 83% of our subjects as Normal, MCI, or Dementia. Furthermore, the
MC-FAQ had a positive predictive value of 95% for discriminating between cognitively normal
elderly individuals from those with MCI or dementia, and it was able to correctly classify 74%
of individuals with MCI. The combination of the MMSE and FAQ had a slightly better ability
to predict the correct diagnosis overall (85% vs. 83%), but at the cost of double or triple the
time necessary to administer the test than the Mini-Cog. In addition, the MMSE-FAQ was
slightly less effective than the MC-FAQ in classifying individuals with MCI (68% vs. 74%).
These results suggest that the administration of the MC-FAQ may be an effective and efficient
approach to widespread screening for cognitive impairment.
Rapid advances in basic and clinical research on AD are expected to yield meaningful
improvements in the treatment of patients with this devastating illness. However, effective
methods must be developed to identify those individuals in the earliest stages of disease to
allow maximal preservation of cognitive abilities. Development of advanced imaging
techniques and effective blood or cerebrospinal fluid biomarkers hold promise for aiding early
detection, but these approaches have major limitations. For example, imaging methods using
new positron emission tomography (PET) tracers to detect development of neuropathological
changes [22,29] are expensive and inaccessible to large portions of the population. Use of
biomarkers often require invasive testing as well as having the limitations of costs and time
required to return results. Moreover, considerable research will be required to establish the
utility of any radiological and biochemical biomarker in tracking true disease progression.
Currently available screening instruments are effective at detecting individuals with overt
dementia, but we are not aware of any established clinical screening instrument for identifying
individuals with MCI. A number of diagnostic approaches have been evaluated, and these have
generally focused on identifying the best cognitive test or battery of tests for detecting MCI
[12,20,28,37]. While some of these methods have shown encouraging results with sensitivities
and specificities ranging from 80% to over 95%, most involved rather complex
neuropsychological tests that are not feasible to deploy in the primary care setting or
community-based screening efforts. Another key limitation in all of these reported methods is
that the cognitive testing is expected to require 15 to 40 minutes to administer. Practical
limitations in current delivery of ambulatory medical care offer compelling motivations for the
development of a much shorter screening instrument to detect cognitive impairment. The 2004
National Ambulatory Medical Care Survey reported that the average duration of an office visit
with a primary care physician was 17.9 minutes [17]. Other estimates suggest that the duration
of office visits may be only 13.3 minutes [16]. The most widely accepted cognitive screening
test, the MMSE [13], typically takes about 10 minutes to administer, and time has been reported
by physicians to be the most common deterrent to performing the MMSE [32]. The MMSE,
used alone, has also previously shown to be neither sensitive nor specific in screening for MCI
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[28]. Large scale screening for MCI and mild dementia will clearly require the development
of a simple, effective, and very brief instrument.
The Mini-Cog has been evaluated previously and shown to have good sensitivity and specificity
for dementia [7,21]. It has often been identified as a good option because it is comparable to
the MMSE in its ability to predict dementia, and it can be administered in an average of 3.2
minutes [6,10,36]. We did not specifically record the time required to administer the Mini-
Cog, but our experience parallels the original report of its brevity [6]. However, the Mini-Cog’s
sensitivity for detecting MCI is only 55% [8]. In addition to cognitive screening tests, a number
of informant-based functional questionnaires have been evaluated as a means of detecting
cognitive decline. The FAQ, which we used in this study, was previously identified by the
Agency for Health Care Policy and Research as an effective means of identifying demented
individuals with sensitivities and specificities in the 85–90% range [11]. Although the FAQ
has not been closely examined as a screener for MCI, greater informant-reported functional
impairment was associated with a higher risk of conversion from MCI to AD during a two-
year follow-up period [31]. A similar increased risk of conversion from MCI to AD was also
recently reported using the Lawton and Brody IADL scale [19,24]. These findings confirm
previous reports that have suggested that cognitively impaired individuals tend to overestimate
their functional abilities [2], and suggest that a functional assessment will enhance the
identification of individuals with very mild cognitive deficits.
Inclusion of a functional assessment questionnaire, such as the FAQ, in screening for MCI
requires that a reliable informant be available and willing to complete the questionnaire. Our
experience in this study suggests that this requirement will not pose a significant impediment
to using the MC-FAQ as a screening instrument. For 97% of subjects, a spouse or other family
member was readily available to provide a functional assessment (either the FAQ or the LB-
IADL), and in most instances, they routinely accompanied the elderly relative to doctor’s
appointments. In cases of elders who live alone and visit clinicians unaccompanied, the need
for an informant to complete the FAQ might pose difficulties, but alternatives, such as
telephone interviews or on-line completion of the questionnaire, may be feasible. Nevertheless,
in most cases, an important practical consideration for the deployment of the MC-FAQ into
primary care settings is that the FAQ can be collected without infringing on the time available
for interaction between patient and clinician. Finally, despite the addition of the FAQ
“functional axis” to the Mini-Cog “cognitive axis”, scoring of the combined MC-FAQ remains
extremely straightforward (see Figure 1), and we anticipate that formal measures will
demonstrate very high inter-rater reliability.
As in most evaluations of screening instruments, the performance of the MC-FAQ in the current
study is likely to have benefited from the high rate of affected individuals in the test population,
and our results will need to be confirmed in the general population. Nevertheless, the current
findings, along with key practical considerations discussed above, suggest that the MC-FAQ
may provide an important and effective screening instrument to improve detection of
individuals with MCI as well as undiagnosed mild dementia.
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A. Distribution of cases along functional (FAQ) and cognitive (Mini-Cog) axes. Classification
based on the MC-FAQ screener can be read off of a simple grid. Cases falling within white
cells are Normal, those in gray cells are MCI, and those in black cells are Dementia. B.
Distribution of cases along functional (FAQ) and cognitive (MMSE) axes. Cases falling within
white cells are Normal, those in gray ells are MCI, and those in black cells are Dementia.
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Table 1
Demographics and test results for three groups of participants
Normal, n = 68 MCI, n = 53 Dementia n = 57
Age 73 77* 81*
Years education 16.0 14.7* 12.5*†
Percent female 63% 73% 81%*
Percent non-white 9% 23%* 37%*
Mini-Cog (0–6) 5.1 3.8* 1.9*†
MMSE (0–30) 29.0 26.9* 19.1*†
FAQ (0–30) 0.5 5.1* 18.4*†
*
Indicates that the either demented or the MCI were significantly (P < 0.05) different from normal group, as evaluated via linear regression with categorical
variables for MCI and demented groups, each compared separately to the normal group. Regressions for Mini-cog, MMSE, and FAQ included variables
for age, gender, education, and race in addition to the categorical variables for MCI and demented.
†
Indicates that the demented group was significantly (P < 0.05) different from MCI group.
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Table 2
Table 2a. Cutpoints for Mini-Cog* and FAQ* to classify participants
Normal MCI Dementia
FAQ 0–2; MC 4–6 FAQ 0–2; MC 0–3
FAQ 3–9; MC 0–6
FAQ 10–12; MC 3–6 FAQ 10–12; MC 0–2
FAQ ⩾13; MC=6 FAQ⩾13; MC 0–5
Table 2b. Cutpoints for MMSE* and FAQ* to classify participants
Normal MCI Dementia
FAQ 0–2; MMSE 27–30 FAQ 0; MMSE 0–26 FAQ 1–30; MMSE 0–25
FAQ 1–2; MMSE 26
FAQ 3–30; MMSE 26–30
Mini-Cog scored 0–6 points with 6 the best score; FAQ scored 0–30 points with 0 the best score.
MMSE scored 0–30 points with 30 the best score; FAQ scored 0–30 points with 0 the best score.
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Table 3
Table 3a. Agreement* of screening test (Mini-Cog + FAQ) and consensus diagnosis
Consensus diagnosis
Diagnosis based on screening test (Mini-Cog + FAQ)
Dementia MCI Normal
Dementia 48 9 0
MCI 2 39 12
Normal 0 7 61
Table 3b. Agreement* of screening test (Mini-Cog + FAQ) and consensus diagnosis
Consensus diagnosis
Diagnosis based on screening test (MMSE + FAQ)
Dementia MCI Normal
Dementia 52 5 0
MCI 6 36 11
Normal 0 5 63
Cutpoints for Mini-Cog and FAQ based on tree algorithm; accuracy 83%, weighted kappa 0.81.
Cutpoints for MMSE and FAQ based on tree algorithm; accuracy 85%, weighted kappa 0.83.
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Table 4
Ability to predict normal, MCI, and dementia based on a polytomous logistic model









Mini-Cog + FAQ 232
MMSE + FAQ 257
The model likelihood is a chi square statistic with 5 degrees of freedom (6 for the last two models with two tests). The model includes 4 demographic
covariates (age, race, sex, education). A higher model likelihood means a better fitting model. An improvement in model likelihood of 3.8 or greater (6.0
or greater for models with two predictive tests) is a statistically significant improvement at the P = 0.05 level. All cognitive tests were highly significant
predictors. Model likelihood with demographic covariates alone was 73.
Based on average of z-scores for two tests in each domain.
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